These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 30306777)
1. Role of the tumor microenvironment in digestive neuroendocrine tumors. Cuny T; de Herder W; Barlier A; Hofland LJ Endocr Relat Cancer; 2018 Nov; 25(11):R519-R544. PubMed ID: 30306777 [TBL] [Abstract][Full Text] [Related]
2. Future perspectives on neuroendocrine tumors. Castellano D; Salazar R; Raymond E Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():35-40. PubMed ID: 21327890 [TBL] [Abstract][Full Text] [Related]
3. The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Cives M; Pelle' E; Quaresmini D; Rizzo FM; Tucci M; Silvestris F Neuroendocrinology; 2019; 109(2):83-99. PubMed ID: 30699437 [TBL] [Abstract][Full Text] [Related]
4. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636 [TBL] [Abstract][Full Text] [Related]
5. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207 [TBL] [Abstract][Full Text] [Related]
6. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939 [TBL] [Abstract][Full Text] [Related]
7. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010 [TBL] [Abstract][Full Text] [Related]
8. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Cloyd JM; Konda B; Shah MH; Pawlik TM Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383 [TBL] [Abstract][Full Text] [Related]
9. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. Turaga KK; Kvols LK CA Cancer J Clin; 2011; 61(2):113-32. PubMed ID: 21388967 [TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors]. Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832 [TBL] [Abstract][Full Text] [Related]
11. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087 [TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Kawasaki K; Fujii M; Sato T Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641 [TBL] [Abstract][Full Text] [Related]
13. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696 [TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Strosberg JR CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930 [TBL] [Abstract][Full Text] [Related]
16. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732 [TBL] [Abstract][Full Text] [Related]
17. The tumour microenvironment of pituitary neuroendocrine tumours. Marques P; Grossman AB; Korbonits M Front Neuroendocrinol; 2020 Jul; 58():100852. PubMed ID: 32553750 [TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Oberg K Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940 [TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065 [TBL] [Abstract][Full Text] [Related]
20. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Cives M; Soares HP; Strosberg J Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]